Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study
Diabetes Care · 01.06.2025 · 48 (6) · 877-886
DOI: 10.2337/dc24-2075 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes Care, online erschienen am 31.01.2025. Verfasst von Cyrielle Caussy und 20 weiteren Autor:innen. Beteiligte Einrichtung: Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: SIEMENS-Healthineers, GILEAD Inc.
Abstract (Originalsprache)
OBJECTIVE Screening for advanced fibrosis (AF) resulting from metabolic dysfunction–associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of noninvasive tests (NITs) with that of two-step algorithms for detecting patients at high risk of AF requiring referral to hepatologists. RESEARCH DESIGN AND METHODS We conducted a planned interim analysis of a prospective multicenter study including participants with type 2 diabetes and/or obesity and MASLD with comprehensive liver assessment comprising blood-based NITs, vibration-controlled transient elastography (VCTE), and two-dimensional shear-wave elastography (2D-SWE). AF risk stratification was determined by a composite criterion of liver biopsy, magnetic resonance elastography, or VCTE ≥12 kPa depending on availability. RESULTS Of 654 patients (87% with type 2 diabetes, 56% male, 74% with obesity), 17.6% had an intermediate/high risk of AF, and 9.3% had a high risk of AF. The area under the empirical receiver operating characteristic curves of NITs for detection of high risk of AF were as follows: fibrosis-4 index (FIB-4) score, 0.78 (95% CI 0.72–0.84); FibroMeter, 0.74 (0.66–0.83); FibroTest, 0.78 (0.72–0.85); Enhanced Liver Fibrosis (ELF) test, 0.82 (0.76–0.87); and SWE, 0.84 (0.78–0.89). Algorithms with FIB-4 score/VCTE showed good diagnostic performance for referral of patients at intermediate/high risk of AF to specialized care in hepatology. An alternative FIB-4 score/ELF test strategy showed a high negative predictive value (NPV; 88–89%) and a lower positive predictive value (PPV; 39–46%) at a threshold of 9.8. The FIB-4 score/2D-SWE strategy had an NPV of 91% and a PPV of 58–62%. The age-adapted FIB-4 score threshold resulted in lower NPVs and PPVs in all algorithms. CONCLUSIONS The FIB-4 score/VCTE algorithm showed excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology. The ELF test using an adapted low threshold at 9.8 may be used as an alternative to VCTE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
- CarMeN Laboratory, INSERM U1060, INRA U1397, Institut National des Sciences Appliquées de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
- Institut d'Hépatologie de Lyon, Lyon, France.
- Department of Endocrinology, Diabetes and Metabolic Disorders, INSERM Unit, Lipides, Nutrition, Cancer (LNC) UMR 1231, Dijon University Hospital, University of Burgundy, Dijon, France.
- Department of Biochemistry, INSERM Unit, LNC-UMR 1231, Dijon University Hospital, University of Burgundy, Dijon, France.
- Hospices Civils de Lyon, Service de Biostatistique, Lyon, France.
ORCID-Profile: Cyrielle Caussy
Förderung
- SIEMENS-Healthineers
- GILEAD Inc
Zitieren
APA
Caussy, C., Vergès, B., Leleu, D., Duvillard, L., Subtil, F., Abichou-Klich, A., Hervieu, V., Milot, L., Ségrestin, B., Bin, S., Rouland, A., Delaunay, D., Morcel, P., Hadjadj, S., Primot, C., Petit, J. M., Charrière, S., Moulin, P., Levrero, M., …, & Disse, E. (2025). Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care, 48(6), 877-886. https://doi.org/10.2337/dc24-2075
Vancouver
Caussy C, Vergès B, Leleu D, Duvillard L, Subtil F, Abichou-Klich A, et al. Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025;48(6):877-886. doi:10.2337/dc24-2075
BibTeX
@article{Caussy2025,
author = {Caussy, Cyrielle and Vergès, Bruno and Leleu, Damien and Duvillard, Laurence and Subtil, Fabien and Abichou-Klich, Amna and Hervieu, Valérie and Milot, Laurent and Ségrestin, Bérénice and Bin, Sylvie and Rouland, Alexia and Delaunay, Dominique and Morcel, Pierre and Hadjadj, Samy and Primot, Claire and Petit, Jean-Michel and Charrière, Sybil and Moulin, Philippe and Levrero, Massimo and Cariou, Bertrand and Disse, Emmanuel},
title = {Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study},
journal = {Diabetes Care},
year = {2025},
volume = {48},
number = {6},
pages = {877--886},
doi = {10.2337/dc24-2075}
}
EUVIMED